MEDI 105-Novel purine derivatives as potent dual Src/Abl tyrosine kinase inhibitors

被引：0

作者：

Wang, Yihan ^{[1
]}

Shakespeare, William C. ^{[1
]}

Huang, Wei-sheng ^{[1
]}

Sundaramoorthi, Raji ^{[1
]}

Lentini, Scott ^{[1
]}

Das, Sasmita ^{[1
]}

Liu, Shuangying ^{[1
]}

Banda, Geeta ^{[1
]}

Wen, David ^{[1
]}

Zhu, Xiaotian ^{[1
]}

Xu, Qihong ^{[1
]}

Keats, Jeff ^{[1
]}

Wang, Frank ^{[1
]}

Wardwell, Scott ^{[1
]}

Ning, Yaoyu ^{[1
]}

Snodgrass, Joseph T. ^{[1
]}

Broudy, Mark I. ^{[1
]}

Russian, Karin ^{[1
]}

Iulucci, John ^{[1
]}

Dalgarno, David ^{[1
]}

Clackson, Tim ^{[1
]}

Sawyer, Tomi K. ^{[1
]}

机构：

[1] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2008年 / 236卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

105-MEDI

引用

页数：1

共 50 条

[31] MEDI 88-Trifluoromethyl substituted pyrrole 2-indolinone derivatives as tyrosine kinase inhibitors
Tang Peng Cho
Bie Ping Yan
Liu Wei Li
Yang Shi Bo
Zhang Lei
Feng Jun
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 235
[32] Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia
Keller-v. Amsberg, Gunhild
Bruemmendorf, Tim H.
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1121 - 1127
[33] Evaluation of Novel Aminomethyl Indole Derivatives as Src Kinase Inhibitors and Antioxidant Agents
Olgen, Sureyya
Kilic-Kurt, Zuhal
Sener, Fatma
Isgor, Yasemin G.
Coban, Tulay
CHEMOTHERAPY, 2011, 57 (01) : 1 - 6
[34] Novel pyrazolopyrimidine derivatives as potent mTOR kinase inhibitors with anticancer activities
Chen, S.
Meng, L.
Liang, C.
Ding, J.
EJC SUPPLEMENTS, 2010, 8 (07): : 54 - 54
[35] Optimization of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors, Leading to the Potent DS08701581
Taniguchi, Toru
Yasumatsu, Isao
Inagaki, Hiroaki
Baba, Daichi
Toyota, Akiko
Kaneta, Yasuyuki
Odagiri, Takashi
Momose, Takayuki
Kawai, Junya
Imaoka, Tomoki
Nakayama, Kiyoshi
ACS MEDICINAL CHEMISTRY LETTERS, 2024,
[36] Design, synthesis, and biological evaluation of bioisosteric analogs of dasatinib as Src, Abl and Abl T315I protein tyrosine kinase inhibitors
Patel, Jay
Chen, Zhe-Sheng
Korlipara, Vijaya
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[37] Novel Anthraquinone-based Derivatives as Potent Inhibitors for Receptor Tyrosine Kinases
Stasevych, M.
Zvarych, V.
Lunin, V.
Halenova, T.
Savchuk, O.
Dudchak, O.
Vovk, M.
Novikov, V.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 (05) : 634 - U167
[38] A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias
Corradi, V
Mancini, M.
Corrado, P.
Barbieri, E.
Santucci, M. A.
Schenone, S.
Botta, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 179 - 179
[39] Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor
Shinya Kimura
Tomoko Niwa
Kazuko Hirabayashi
Taira Maekawa
Cancer Chemotherapy and Pharmacology, 2006, 58 : 55 - 61
[40] Potent inhibition of imatinib-resistant variants of Ber-Abl by a novel dual selective Src/Abl kinase inhibitor AP23464: Implications for CML therapy.
O'Hare, T
Stoffregen, EP
Abdullah, OM
Deininger, MW
Rivera, VM
Tang, H
Keats, JA
Metcalf, CA
Wang, YH
Sundaramoorthi, R
Shakespeare, WC
Dalgarno, D
Sawyer, TK
Druker, BJ
BLOOD, 2003, 102 (11) : 20A - 20A

← 1 2 3 4 5 →